A downtrend has been apparent in Inovio Pharmaceuticals (INO) lately with too much selling pressure. The stock has declined 32.7% over the past four weeks. However, given the fact that it is now in ...

PLYMOUTH MEETING, Pa., Nov. 13, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from ...

The last time I spoke about Inovio Pharmaceuticals (INO) it was with a Seeking Alpha article entitled "Inovio: Back On Track With INO-3107 BLA For RRP Before End Of 2025." With respect to this article ...

CEO Jacqui Shea highlighted that Inovio remains committed to transforming into a commercial-stage company, with a primary ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

CEO Jacqueline Shea highlighted that "these are very exciting times for Inovio with our first BLA for INO-3107 as a potential treatment for adults with recurrent respiratory papillomatosis or RRP, ...

Inovio Pharmaceuticals INO makes DNA medicines to potentially treat and prevent diseases associated with human papillomavirus (HPV), cancer and infectious ailments, using its proprietary optimized ...

Good afternoon, ladies and gentlemen, and welcome to the Inovio's second quarter 2021 financial results conference call. [Operator instructions] This call is being recorded on Thursday, August 8th, ...

With that, I’ll turn it over to our Chief Commercial Officer, Steve Egge to provide an update on the commercial front. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2025 Earnings Call Transcript ...